stj 2016 analyst and investor day presentation v2

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE

BULLET GUIDE BULLET GUIDE

ST. JUDE MEDICAL

2016 ANALYST AND

INVESTOR MEETING February 5, 2016

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


WELCOME AND OPENING REMARKS Mike Rousseau, President and CEO

2

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


This presentation contains forward-looking statements within the meaning of the Private Securities Litigation

Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the

expectations, plans and prospects for the Company, including potential clinical successes , reimbursement

strategies, anticipated regulatory approvals and future product launches, and projected revenues, margins,

earnings and market shares. The statements made by the Company are based upon management’s current

expectations and are subject to certain risks and uncertainties that could cause actual results to differ

materially from those described in the forward-looking statements. These risks and uncertainties include

market conditions and other factors beyond the Company’s control and the risk factors and other cautionary

statements described in the Company’s filings with the SEC, including those described in the Risk Factors

and Cautionary Statements sections of the Company’s Annual Report on Form 10 -K for the fiscal year ended

January 3, 2015 and Quarterly Report on Form 10-Q for the fiscal quarter ended October 3, 2015. The

Company does not intend to update these statements and undertakes no duty to any person to provide any

such update under any circumstance.

The Company will be using non-GAAP financial measures (e.g., constant currency sales growth, adjusted net

earnings, etc.) in this presentation. Investors should consider non-GAAP measures in addition to, and not as a

substitute for, financial performance measures prepared in accordance with GAAP. For a reconciliation of our non-

GAAP financial measures to our GAAP results, please see the Company’s Current Report on Form 8-K furnished

January 27, 2016.

FORWARD-LOOKING STATEMENTS AND DISCLOSURES

3

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


8:00AM Driving Growth Through Innovation

Mike Rousseau, President and Chief Executive Officer

Thoratec Integration: A Priority for 2016

Rachel Ellingson, V.P., Corporate Strategy

Heart Failure: Medical Technology Leadership

Eric Fain, M.D., Group President

John O’Connell M.D., Medical Director, Mechanical Circulatory Support and V.P., Medical Affairs

Panel for Q&A

~10:00AM Break

Atrial Fibrillation: Platform and Pipeline for Global Innovation Leadership

Phil Ebeling, V.P. and Chief Technology Officer

Traditional CRM: A Path to Recovery in the U.S.

Eric Fain M.D., Group President

Neuromodulation: Building the Most Comprehensive Portfolio

Keith Boettiger, Senior V.P. & General Manager, Chronic Pain & Movement Disorder Therapies

Cardiovascular: Products to Watch in 2016

Phil Ebeling, V.P. and Chief Technology Officer

Panel and Q&A

12:00PM Meeting Ends

AGENDA

4

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


QUOTE GUIDE QUOTE GUIDE

QUOTE GUIDE QUOTE GUIDE

OUR COMMITMENT TO CUSTOMERS

Target expensive epidemic disease states by surrounding the patient

care continuum with innovative products that offer clinical and

economic advantages

5

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


Growth

Heart Failure Low/Mid SD

Atrial Fibrillation Low-teens

Neuromodulation Mid/High SD

Traditional CRM Flat

Cardiovascular High-single/Low-teens

OUR MARKETS FOR 2016 EXCEED $23 BILLION IN SIZE AND ARE

GROWING MID SINGLE DIGITS*

>$4B

>$2B

>$4B

~$7B

>$6B

Atrial Fibrillation Neuromodulation

Heart Failure Traditional CRM

Cardiovascular

All dollar market sizes are based on estimated revenues

St. Jude Medical market estimates

* Excludes the impact from currency

Low/Mid SD- Low to middle single digit percent growth

Low-teens - Low teens percent growth

Mid/High SD-Middle to high single digit percent growth

High-single/Low-teens percent growth

Flat ~0%

6

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


Atrial Fibrillation (AF): We understood early on that ultimately curing AF would require a “tool box” approach

Over time, we have created the most comprehensive product portfolio in the industry

Heart Failure: We are on the front lines of developing the multi-billion dollar heart failure device market

We are uniquely able to offer products that improve patient care – from early symptoms to advanced heart failure,

regardless of type

The recent acquisition of Thoratec adds the market leading portfolio of left ventricular assist devices

Neuromodulation: We are the global innovation leader with a portfolio that spans the continuum of care for chronic

pain patients

STJ proprietary SCS Burst therapy* provides superior pain relief vs. tonic for overall, trunk, and limb pain

STJ’s proprietary Dorsal Root Ganglion therapy* is superior to tonic relief for targeted pain syndromes

SURROUNDING DISEASE STATES

7 *Caution - INVESTIGATIONAL DEVICE, LIMITED BY FEDERAL (OR UNITED STATES) LAW TO INVESTIGATIONAL USE.

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE

BULLET GUIDE BULLET GUIDE Healthcare remains a largely fee-for-service market

Economic incentives need to change for providers to truly transition to fee-for-value

Industry needs to address both ends of the spectrum

We are living this paradigm with technologies like CardioMEMS/Fractional Flow Reserve (FFR)

We are working with customers during this transition to provide tailored solutions

Markets around the world are evolutionary not revolutionary when it comes to the paradigm shift

from fee-for-service to fee-for-value

ADDRESSING AN EVOLVING HEALTHCARE LANDSCAPE

FFS = fee-for-service / FFV = fee-for-value

FF

S

FF

V

8

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


9

In 2012 we saw: our markets changing, hospitals consolidating, payment models

transitioning, pricing pressures mounting

How can STJ compete and win in that environment?

Target expensive epidemic disease states and deliver innovation to transform treatment in

those markets

Surround patient care continuum with products that offer clinical and economic advantages

Provide solutions to our customers that address their needs in an evolving healthcare

landscape

And transition from a highly decentralized structure to ONE SJM (end of 2012)

Agility being critically important

Resources must be optimized across organization

OUR DECISION TO EVOLVE OUR STRUCTURE

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


Aligned priorities ensure global organization focused on the right things

Shared resources across our organization – able to make decisions based on company-wide goals

rather than individual division goals

Faster decision making and ability to course correct – agility is critically important

Operating leverage through global supply chain

Drives increased collaboration and communication without expense of traditional business silos

Cultural alignment – employees working together to achieve our vision and mission

Integration as a competitive advantage

Selling divisions can focus on selling – organized the way customers make purchasing decisions

Contracting resources within selling teams across cardiovascular service line

OUR STRUCTURE SUPPORTS OUR STRATEGY

Functional Centers of

Excellence Geographic and Key

Accounts Sales Teams

10

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


11

Atrial Fibrillation:

Addressed ablation catheter gap and now adding a highly competitive advanced mapping

system with a full set of tools

EnSite Precision* – 18 months from development to launch

FlexAbility SE Catheters**

Neuromodulation:

Transformed neuromodulation business through internal investment and acquisitions by

reallocating significant resources

Launching most comprehensive portfolio in 2016

Heart Failure:

Identified challenges in treatment paradigm and invested resources to become medical

technology leader

HeartMate LVAD / CardioMEMS opportunities in 2016; MultiPoint™ Pacing*** for non-

responders

ONE SJM – MANY BENEFITS

*510K pending

**PMA-S pending

****Caution - INVESTIGATIONAL DEVICE, LIMITED BY FEDERAL (OR UNITED STATES) LAW TO INVESTIGATIONAL USE.

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


2016 GOALS

12

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


Establish U.S. reimbursement for CardioMEMS nationwide

Successfully integrate our Thoratec acquisition

Execute the plan for recovery in U.S. CRM

Successfully launch key products to drive sales growth

Where we focus…We win

SETTING MEASURABLE GOALS IN 2016

13

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


We have clear evidence that pulmonary artery pressure-guided heart failure management is

superior to clinical assessment alone

Recent The Lancet publication: 48% reduction in HF hospitalizations at 31 months

CMS established new technology add-on and pass-through pathway payments

We have submitted our application to CMS for a National Coverage Determination

We will also continue to work with national private payers and regional MACs

Our commercial experience has continued to demonstrate strong patient benefits and there is

tremendous support from the implanting community

Clinical evidence continues to grow and outcomes are as good as – or better than – those observed in

CHAMPION

ESTABLISH U.S. REIMBURSEMENT FOR CARDIOMEMS

14

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


Thoratec represents the largest acquisition in the history of St. Jude Medical

Added the broadest portfolio of mechanical circulatory support devices to treat the full

range of clinical needs for patients suffering from advanced heart failure

Integration team and priorities were established early

Appointed an executive sponsor, dedicated senior leader and cross-functional team to ensure

stability within both organizations

Continued business momentum demonstrated with revenue growth and clinical study

execution

A TOP PRIORITY FOR ST. JUDE MEDICAL

HeartMate 3™ System*

HeartMate PHP™ System*


CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


Upcoming launches will fill product gaps as well as deliver technology advancements

Allow STJ to compete at the premium tier of contract negotiations

Enhanced AF, HF and CRM portfolios provide unique opportunities when contracting with

customers

First half of 2016:

Assurity MRI™ Pacemaker* in the U.S.

MRI labeling for existing ICD’s in Japan

MRI safe Ellipse™ ICD approved on February 2, 2016

Second half of 2016:

Nanostim™ Leadless Pacemaker*

MultiPoint™ Pacing*, advanced diagnostics, next generation Confirm™ insertable cardiac

monitor**

OUR PATH TO RECOVERY IN CRM BEGINS WITH UPCOMING LAUNCHES

16 *Caution - INVESTIGATIONAL DEVICE, LIMITED BY FEDERAL (OR UNITED STATES) LAW TO INVESTIGATIONAL USE

**Product not available for sale; remains in development

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


SIGNIFICANT INVESTMENT IN FUTURE INNOVATION

Notable 2016 Investments:

Portico™ IDE trial: Over 1,200

randomized subjects*

Heartmate PHP™ Shield II trial: 425

patients*

Initiate Amplatzer Amulet IDE study

Initiate EnligHTN Renal Denervation IDE

study

Dual chamber leadless pacing

development work

Next-generation LVAD technology

Next-generation Confirm™ insertable

cardiac monitor**

Portico™ Transcatheter Aortic Valve

EnligHTN™ multi-electrode renal

denervation system

Nanostim™ leadless pacemaker

Confirm™ Insertable Cardiac Monitor



CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


INCREASING SHAREHOLDER VALUE

Intensify our FOCUS by surrounding disease states

Heart Failure, Atrial Fibrillation, Neuromodulation

Prioritizing programs and resources to surround care continuum

Continue to invest in INNOVATION to raise standards of care

Innovation leadership is our competitive advantage

Leverage CRM technology portfolio and expertise

Further develop ONE SJM CULTURE to mobilize employees

In support of our mission; driving productivity, commitment and teamwork

Strengthen EXECUTION and grow markets and sales

Product launches, market development and operating leverage

Deliver on EXPECTATIONS of our stakeholders

Doing what we say we are going to do

18

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

TITLE GUIDE TITLE GUIDE

SUBHEAD GUIDE SUBHEAD GUIDE

THORATEC INTEGRATION:

A PRIORITY FOR 2016 Rachel Ellingson, V.P., Corporate Strategy

19

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER


HEADER GUIDE HEADER GUIDE

Together as one company, we offer patients and physicians the most

comprehensive portfolio of products across the heart failure (HF) care

continuum

Expand the reach of left ventricular assist devices (LVADs) for advanced

stage HF

Integrate our technologies for improved therapy options

Leverage our global presence and enter new markets

Together we will lead the industry in heart failure management

BUILDING THE WORLD LEADER IN HEART FAILURE MANAGEMENT

20

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER



Full integration of Thoratec within the STJ global structure

The integration team is focused on:

Collaboration

Momentum

Organization

Culture

Speed

INTEGRATION GUIDING PRINCIPLES

21

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


Maintain business momentum and leverage STJ’s expertise in HF, size and

distribution network as quickly as possible

Drive revenue growth through scale and by offering customers the broadest

portfolio of HF products

Deliver exceptional customer experience

Drive innovation leadership and doing so more efficiently through STJ

technology platform capabilities

Leverage cost and productivity synergies through integrated operations,

distribution and infrastructure

Implement “One St. Jude Medical” for organizational design and cultural

alignment

Identify and grow top talent across the business

INTEGRATION PRIORITIES

22

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


Cultural alignment is a critical success factor in any merger or acquisition

St. Jude Medical and Thoratec have a shared commitment to:

Patients

Customers

Delivering innovation to save and improve lives

Our cultures have many areas of alignment – we expect to grow stronger

together by leveraging our differences

CULTURAL ALIGNMENT

23

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


Revenue diversification and broader scale to our heart failure program

Business momentum continues with Q4 revenue beating expectations

Significant progress on cross-training sales and clinical resources

Revenue and cost synergies overachieving deal model

Provides incremental operating leverage and significant accretion in 2016 estimated

to be approximately $0.20 per share

Operational improvements

Manufacturing optimization and site consolidation

Joint cross-functional integration team in place and performing well

Functional integration plans have been developed

All employees reporting in “One St. Jude Medical” structure

PROGRESS

24

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


Q1 2016 Executing functional

integration plans; key infrastructure

milestones

October 8

Acquisition completed;

Integration kick-off

First 60 Days

One STJ reporting; 2016 AOP

developed; Key site decisions made

Mid-2016 Fully functioning as

an integrated business

INTEGRATION CADENCE

25

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


HEART FAILURE: MEDICAL

TECHNOLOGY LEADERSHIP Eric Fain, M.D., Group President

John O’Connell M.D., Medical Director, Mechanical

Circulatory Support and V.P., Medical Affairs

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE




27

HEART FAILURE – THE MARKET

71% 7%

2%

20%

CRT-D

CRT-P

CMEMS

LVAD

2016 Market Revenue >$4B

Market Growth*: Low to mid-single digits

* excludes the impact from currency


2016* Market Growth Expectations

WW: 2%-4%

U.S.: 3%-4%

Intl: 2%-3%

Market dynamics impacting the heart

failure market in 2016:

Destination therapy continues to be

primary growth driver WW for VADs

Establishing reimbursement for remote

hemodynamic monitoring

Continued shift in global markets to CRT,

increase in de novo mix, and premiums

for new technologies

~$300 million worldwide CRT-P

market growing in the high-single

digits

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


HEART FAILURE BURDEN1,2

26M HF sufferers globally3

15M Europeans

5.1M Americans suffer from HF

>650,000 new HF diagnoses each year

1 in 2 HF patients die in 5 years

Burden on the U.S. healthcare system is high

2.8M office and emergency department visits each year

1.0M HF hospitalizations each year

Leading cause of hospitalizations among patients >65 years old

Class III and IV HF patients represent ~75% of hospitalizations4,5

Every 30 seconds, someone is hospitalized for HF

U.S. in particular focused on new approach to reduce hospitalizations

and improve outcomes

Heart Failure is a growing and expensive public health issue

of HF patients

die in 5 years1

50% 5.1M

28

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


New York Heart Association (NYHA) Classification

II III IV

Intervention

or

Procedure

Percent of

Symptomatic

HF Population

48%

~12.5M patients†

39%

~10.1M patients†

13%

~3.4M patients†

Percent of HF

Admissions

20%

~200,000 admissions‡

44%


32%


Cardiac Resynchronization Therapy (CRT)

CardioMEMS™ HF

System

LVAD: Short and Long Term

HEART FAILURE THERAPY CHARACTERIZED BY THREE PRIMARY

DEVICE INTERVENTIONS1,2,3

†Based off 26M patients WW3 ‡Based on 1M U.S. admissions

29

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


SUSTAINING LEADERSHIP IN CRT

30

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


STJ QUADRIPOLAR INNOVATION SET THE NEW STANDARD OF CARE:

SUBSTANTIATED BY 100K+ IMPLANTS & 130+ PUBLICATIONS

Finding Citation

97% implant success rate6

40.8% risk reduction in LV lead related events7

19% improvement in responder rates at 12 months7

44% relative reduction in non-responders7

$2,197 patient cost savings at 180-days post implant8

18% reduction in mortality9 2014

2014

2014

2014

31

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


Problem Statement

Non-responders remain a significant issue

even with advances in CRT technology

Cannot identify non-responders at implant

Solution: MPP provides an additional set of non-

invasive tools -- pacing from two locations on a single

lead to optimize and tailor CRT therapy

Tailor effective therapy

Improve outcomes for complex HF patients

Salvage non-responders or create super-responders

New Advanced Quadripolar Pacing Options**

Supplemental lead shapes for optimal placement*

Auto VectSelect Quartet™ Multivector Testing

MULTIPOINT™ PACING (MPP)*

THE NEXT GENERATION IN QUADRIPOLAR TECHNOLOGY

* Caution - INVESTIGATIONAL DEVICE, LIMITED BY FEDERAL (OR UNITED STATES) LAW TO INVESTIGATIONAL USE

** WW launch beginning in 1H 2016 32

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


-4%

-2%

0%

2%

Q4'12 Q1'13 Q2'13 Q3'13 Q4'13

Growing body of evidence and real-

world experience continue to build

60 abstracts/publications to date

Experience in international markets an

analog for U.S. opportunity

Driver for share capture

Continued mix shift (now > 50% of CRT

with ASP premium in markets where

available)

Available in both CRT-D and CRT-P

Expect U.S. launch 2H 2016

MORE-CRT MPP Study:

Investigating conversion of non-

responders by MPP (~1,800 patients)

Expect to complete enrollment 1H 2016

MULTIPOINT PACING*: STJ INNOVATION FOLLOWING IN THE

FOOTSTEPS OF QUADRIPOLAR TECHNOLOGY

MDT quad

approval

STJ MPP approval

Finding Citation

Improved acute hemodynamic

response10-13

Increased Ejection Fraction14

Improved reverse remodeling15

19% improvement in responder rates at 12-

months16

44% relative reduction in non-responders16

Improved NYHA class17

Converted non-responders to responders17

STJ CRT-D Unit Share Shift: EMEA

33 * Caution - INVESTIGATIONAL DEVICE, LIMITED BY FEDERAL (OR UNITED STATES) LAW TO INVESTIGATIONAL USE

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


ADVANCING HF STANDARD OF CARE

WITH CARDIOMEMS

34

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


CURRENT BEST PRACTICE PROVEN TO BE INEFFECTIVE ACROSS

NEARLY 5,000 PATIENTS

Trial N Parameter Monitored/

Clinician Interaction

Impact on HF

Hospitalization Citation

TEN-HMS18 426 Signs/symptoms, daily weights,

BP, nurse telephone support None

TELE-HF19 1,653 Signs/symptoms, daily weights None

TIM-HF20 710 Signs/symptoms, daily weights None

INH21 715 Signs/symptoms, telemonitoring,

nurse coordinated DM None

BEAT-HF22 1,437

Pre-D/C HF education, regularly

scheduled telephone nurse

coaching & remote monitoring of

weight, BP, HR, signs/symptoms

None

Total 4,941

2010

2011

2005

2015

2012

35

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


CARDIOMEMS IS DIFFERENT: IT ENABLES TREATING PATIENTS

BEFORE THEY EXHIBIT SYMPTOMS

Graph adapted from Adamson PB, et al. Curr Heart Fail Reports, 2009.

Only CardioMEMS HF System enables proactive management of patients

before visible symptoms, shown to reduce HF hospitalizations by 37%23

STJ proprietary

solution

PA

Pressure

36

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


CARDIOMEMS HF SYSTEM EVIDENCE CONTINUES TO GROW

33 KEY PUBLICATIONS/ABSTRACTS AND COUNTING

37% Reduction in HF

hospitalizations at average

15-month follow-up20

48% Reduction in HF hospitalizations

when control group has access

to PA pressure monitoring21

Durability of treatment group

in absence of nurse

communications21 31

50% Reduction in heart failure

hospitalizations within HFpEF

population at average 18-

month follow-up22

Reduction in 30-day heart

failure readmissions in

Medicare population23 78%

53% Survivability improvement of

HFrEF treatment group

compared to guideline directed

medical therapy (GDMT) and

ICD/CRT therapy25

2010

2015

2015

2014

2014

2015 MO

NT

HS

37

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


Heart failure with reduced ejection fraction (HFrEF; EF<40%)

~50% of total HF population (~13M WW)

Indicated for guideline determined medical therapy, ICD, and/or CRT therapies

Heart failure with preserved ejection fraction (HFpEF; EF>40%)

~50% of total HF population (~13M WW)

Underlying root causes not well understood,

no consensus GDMT

No solutions previously proven

prior to CardioMEMS

HF hospitalization rates equal to or

higher than HFrEF patients

CardioMEMS hemodynamic-guided HF therapy

is the 1st strategy to improve outcomes in HFpEF

Estimated at NNT = 2

HFpEF: ADDRESSING A LARGE UNDERSERVED HF POPULATION

38

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


Clinical outcomes have been as good or better than observed in CHAMPION*

Training approach and integration into HF clinics has been validated in real world

Learning to proactively manage to pressure versus reactively responding to symptoms

or weight /blood pressure changes

New workflow

Manageable weekly review of trends

Replaces traditional non-reimbursable activities for clinicians such as regular and

patient-initiated phone calls, unscheduled clinic and ER visits and addressing symptomatic

patients

The reality of HF penalties29

Facilities with higher readmission rates now incur up to a 3% reduction in total Medicare

payments

Less than 25% of hospitals subject to the Hospital Readmissions Reduction Program

performed well enough on the CMS' 30-day readmission program to face no penalty

CARDIOMEMS IN THE “REAL WORLD”

39 *Interviews with doctors regarding specific results. Results may vary

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


Reimbursement headwinds not atypical for new technologies

Favorable reimbursement at national level (NTAP and TAPTS)

Challenges at the local Medicare Access Carrier (MAC) level being addressed

and supported by new longer term data and publications

Novitas

Draft Local Coverage Determination (LCD) pending review of open comments

Expect decision 1Q 2016

First Coast Service Options (FCSO)

Reconsideration application for previous negative LCD submitted December 2015 and was

accepted January 2016

Expect decision 1Q 2016

IMPROVING REIMBURSEMENT TO ACHIEVE STANDARD OF CARE

40

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


Pursuing CMS National Coverage Determination (NCD)

Initiated discussions with CMS in October 2015

Submitted NCD draft in December 2015

Submitted formal NCD application January 29, 2016

NCD applies nationally to all Medicare beneficiaries and supersedes any LCDs

Possible outcomes: Coverage, No coverage, Coverage with Evidence Development (CED)

CED provides coverage while additional data is collected to continue developing the evidence base

Common mechanism used by CMS to provide coverage for new technologies (e.g., TAVR, TMVR and LAA)

Expected Timeline/Process*

CMS NATIONAL COVERAGE DETERMINATION

NCD

Submitted

1/29/16

JAN

CMS

Decision

to Accept

Request

<FEB-MAR

End of

Public

Comment

Period

(30 days)

<OCT

Proposed

Decision

Released

(6 months from

acceptance)

End of

Public

Comment

Period

(30 days)

<SEP

Final Decision

Released

(within 60 days of

end of comment

period)

<DEC <MAR-APR

*Optional HTA or MEDCAC meeting adds ~3 months, but considered unlikely (not done for TAVR, TMVR or LAA)

2016 2017

41

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


NEAR-TERM EVOLUTION OF CARDIOMEMS PLATFORM:

MERLIN.NETTM 9.0

Merlin.net Website myMerlinTM application EHR Integration

Patient receives medication

updates via smartphone app

Designed for both iPhone and

Android use

Bi-directional communication for

patient acknowledgement or

escalation

Further automates communication

with patient

Further eliminates/reduces phone

calls while documenting interventions

Technology-enabled prescription

adjustments

Medication updates electronically

pushed to patient’s smartphone

CardioMEMS notifications displayed

in EHR system directly

Allows CardioMEMS discrete data to

be selectively integrated into practice

EHR

Enables single site login within EHR

and Merlin.net to further streamline

workflow and leverage practice

system of record 42

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


Our goal is to be the innovation and solution leader in HF

SUMMARY

Cardiac Resynchronization

Therapy (CRT) CardioMEMS HF System

Left Ventricular Assist

Devices (LVADs)

Product, Patient and Customer Synergies for Managing Heart Failure

CardioMEMS + CRT in Merlin.net

CardioMEMS-guided CRT programming & CardioMEMS-guided LVAD

Contracting across HF care pathway

43

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


HEART FAILURE: MECHANICAL

CIRCULATORY SUPPORT John O’Connell M.D., Medical Director, Mechanical

Circulatory Support and V.P., Medical Affairs

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


45

2,500

5,000

76% 93% 69% 66%

2014 2015 (est) 2013 2012

Notes:

(1) In the U.S. excludes HVAD stocking units prior to 2015.

(2) Excludes PVAD and market participants other than Thoratec and Heartware.

(3) U.S.- Q4’14 excludes a 53rd week for THOR

(4) OUS-Q4’14 excludes a 53rd week for THOR

HEARTMATE 3TM OFFERS NEAR-TERM OPPORTUNITY

FOR SHARE CAPTURE IN INTERNATIONAL MARKETS

5,000

2,500

0

2014 2015 (est) 2012 2013

42% 47% 47% 40%

HeartMate(HM)

HTWR

U.S. Market (Units) International Market (Units)

HM 3 offers opportunity for

share capture OUS

HM exited 4Q 2015 with ~73% share

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


46

GROWTH DRIVEN BY TREMENDOUS BENEFITS OF THERAPY

0%

25%

50%

75%

100%

Baseline 6 Months

Bridge to Transplantation at 6 Months

0%

25%

50%

75%

100%

Baseline 2 Years

Destination Therapy at 2 Years

Improvement in NYHA Functional Class Over Time30

Could not

complete 345 m

average

Only 16% could complete

pre implant

94% could complete

post implant

Bridge-to-Transplantation Six-Minute Walk Test (6MWT)31,32

NYHA IV

NYHA III

NYHA II

NYHA I

Can’t Walk Can Walk

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


HEARTMATE IITM IMPROVED ADVERSE EVENT RATES

Device RelatedInfection

Bleeding RequiringSurgery

Pump Replacement Isc Stroke Hem Stroke Hemolysis Thrombus

Trial PAS

0.06

0.031

0.47

0.22 0.07

0.052

0.024

0.06

0.024 0.027

0.23

0.09

0.057

0.026

Events/pt-year

Note: 3x scale difference for Device infection and Bleeding requiring surgery compared to others

Jorde, Khushwaha, Tatooles, et al. JACC 2014

Destination Therapy Trial vs. Post Approval Study (PAS)

47

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


HEARTMATE II LEFT VENTRICULAR ASSIST SYSTEM IS

THE MOST WIDELY USED AND EXTENSIVELY STUDIED LVAD

Strong body of evidence

> 22,000 patients implanted

> 1,300 patient clinical trial (BTT & DT)

Extensive post-market study experience

with highly challenging patient populations

> 720 published, peer-reviewed articles

Reliability demonstrated by

> 2,000 patients at 3+ years of

support (longest >10 years)

Benefits continue to improve

over time

68% 73% 74%

Trial CAP PostApproval

68% 74%

85%

Trial CAP PostApproval

Bridge-to-

Transplant33

Destination

Therapy34

1-Year Survival Rates

48

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


HEARTMATE 3 WITH FULL MAGLEVTM TECHNOLOGY FURTHER

STRENGTHENS COMPETITIVE POSITION

Design objectives

Reduced adverse events

Compact size for less invasive surgical

approaches

Return of pulsatility into continuous flow profile

Full support (flow) up to 10L/minute at lower

pump speeds

Large and consistent gaps allow for thorough

washing and avoidance of blood trauma (shear)

Caution - INVESTIGATIONAL DEVICE, LIMITED BY FEDERAL (OR UNITED STATES) LAW TO INVESTIGATIONAL USE. 49

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


0.50

0.60

0.70

0.80

0.90

1.00

0 1 2 3 4 5 6

Perc

en

t S

urv

ival

Months

Estimated SHFM

HM3 actuarial survival

92%

78%

Estimated hazard ratio for the HM3 = 0.34

P = 0.0093

HeartMate 3 reduced the 6-month mortality risk by 66%

6-MONTH HEARTMATE 3* RESULTS IN IMPROVED SURVIVAL VS.

PREDICTED MEDICAL SURVIVAL USING SEATTLE HF MODEL

*Caution - INVESTIGATIONAL DEVICE, LIMITED BY FEDERAL (OR UNITED STATES) LAW TO INVESTIGATIONAL USE. 50

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


HEARTMATE 3** HAS A FAVORABLE ADVERSE EVENT PROFILE

Days 0 – 30

(n=50)

Days 0 – 180

(n=50)

Event #

Pts

%

Pts

#

Events

#

Pts

%

Pts

#

Events

Bleeding 15 30% 19 19 38% 35

Requiring Surgery 6 12% 6 7 14% 8

GI 2 4% 2 4 8% 6

Any Infection 10 20% 14 18 36% 28

Sepsis 4 8% 4 8 16% 8

Driveline 1 2% 1 5 10% 5

Stroke 2 4% 2 6 12% 6

Ischemic 2 4% 2 4 8% 4

Hemorrhagic 0 0% 0 2 4% 2

Neurologic Dysfunction* 2 4% 2 4 8% 4

Right Heart Failure 4 8% 4 5 10% 5

Requiring RVAD 2 4% 2 2 4% 2

Pump Malfunction 0 0% 0 0 0% 0

Pump Thrombosis 0 0% 0 0 0% 0

Hemolysis 0 0% 0 0 0% 0

*TIA, seizures

**Caution - INVESTIGATIONAL DEVICE, LIMITED BY FEDERAL (OR UNITED STATES) LAW TO INVESTIGATIONAL USE. 51

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


European limited market release 4Q 2015, full market release by the end of 1Q 2016

CE Mark approved mid-October 2015

30+ centers actively implanting by the end of 2015 (including major German centers)

200+ devices implanted through end of 2015

MOMENTUM 3 U.S. IDE Study (currently enrolling)

Over 1,000 patients at up to 60 U.S. sites (548 enrolled as of January 2016)

Single study design for short and long term use

First 294 patients with six month follow up (enrollment completed in October 2015)

Short-term indication FDA submission expected 2H 2016

First 366 patients with two year follow up (enrollment completed in November 2015)

Approximately 600 additional patients to evaluate Secondary Endpoints

Non-inferiority study randomized 1:1 against HeartMate IITM

Primary Endpoints: Survival on HeartMate 3 support free of stroke or pump replacement

HEARTMATE 3* PROGRAM IS ON-TRACK


CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


St. Jude Medical offers the broadest portfolio of mechanical circulatory support devices to treat the

full range of clinical needs for patients suffering from advanced HF

HeartMate II is the most widely used and extensively studied LVAD on the market

HeartMate 3 is a next generation LVAD with the first fully magnetically levitated compact VAD

MOMENTUM 3 IDE study continues to enroll

First quarter of the European launch was a success

Will complete the full rollout by the end of 1Q 2016

Short-term indication FDA submission 2H 2016

SUMMARY

53

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

54



Q&A Panel Moderator:

Mike Rousseau, President and CEO

Panelists:

Phil Adamson, M.D., Medical Director and V.P., Medical Affairs


John O’Connell, M.D., Medical Director, Mechanical Circulatory Support and V.P., Medical Affairs

Don Zurbay, Chief Financial Officer

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

55



St. Jude Medical Important Dates in 2016:

First quarter 2016 earnings results conference call: April 20, 2016

Second quarter 2016 earnings results conference call: July 20, 2016

Third quarter 2016 earnings results conference call: October 19, 2016

MID-MORNING BREAK

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


ATRIAL FIBRILLATION:

PLATFORM AND PIPELINE FOR

GLOBAL INNOVATION

LEADERSHIP Phil Ebeling, V.P. and Chief Technology Officer

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE




31%

16%14%

16%

11%8%

4%

EP AblationEP DiagnosticEP Mapping and Recording SystemsCardiac MonitorsAccessICE/OtherLAA Closure

ATRIAL FIBRILLATION (AF) – THE MARKET


Market Growth*: Low double digits

*excludes the impact from currency



WW: 11%-12%

U.S.: 12%-14%

Intl: 9%-10%

Market dynamics impacting the AF market

in 2016:

~2.5% of the diagnosed symptomatic AF

patient population receiving ablation

Strong growth in ablation driven by catheter

ablation and advanced technology adoption

WW ablation procedures projected to reach

almost 950K in 2016 (double digit growth)

Force-sensing catheters quickly becoming

standard of care

Continued steady catheter ablation growth

expected for U.S. patients diagnosed with AF

57

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


ELECTROPHYSIOLOGY (EP) ABLATION MARKET IS ~75%

IRRIGATED/ADVANCED ABLATION

Revenue in Millions

U.S. Catheter Ablation

Procedures estimated to be ~270K in 2016 (8% growth)

In two years over 50% of the U.S. irrigated ablation

catheter market moved to contact force

Market revenue growing at 17% (’13-’16 CAGR)

STJ expects to gain multiple share points in 2016

WW Catheter Ablation

Procedures estimated to be ~950K in 2016 (10% growth)

Market revenue growing at 11% (’13-’16 CAGR)

STJ expects to gain multiple share points in 2016

$0

$1,400

US WW

Estimated 2016 Catheter Ablation Market Size1

Standard Irrigated/Advanced

58

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


INTEGRATED EP PRODUCT PORTFOLIO

WorkMate™ ClarisTM

Recording

System (1.1/1.1.1 software)

***MediGuideTM Technology

17.0 software,

**CRT 2.0 tools, Quadra Excel™

Guidewire, Sensor Enabled™

VantageViewTM System

HD display with add-on tools

***EnSite PrecisionTM

Cardiac Mapping System

TactiCathTM Quartz

Contact Force Ablation Catheter

**TactiCath™

Contact Force Ablation Catheter,

Sensor Enabled™

FlexAbilityTM

Ablation Catheter

*FlexAbility™

Ablation Catheter, Sensor Enabled™

AmpereTM

RF Ablation Generator

Cool PointTM

Irrigation Pump

AgilisTM NxT

Steerable Introducers

SwartzTM

Braided Transseptal Guiding

Introducers

BRKTM

Transseptal Needles

Access and Guidance

Advanced Ablation Recording Mapping

and Navigation Diagnostics and

Visualization

ViewFlexTM and ViewMateTM

Intracardiac Ultrasound

Reflexion™

Spiral Variable Radius Mapping

Catheters

LiveWireTM and InquiryTM

Steerable Catheters

ResponseTM and SupremeTM

EP Catheters

**Advisor™

FL Circular Mapping Catheter,

Sensor Enabled™

**Next Generation Confirm ™

STJ Integrated Lab

Complete Ablation Solution

*PMA under review


***510K pending

59

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


FLEXABILITY AND TACTICATH ABLATION CATHETERS

60

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE




LOWER AF RECURRENCE AND SHORTER PROCEDURE TIMES USING

CONTACT FORCE1,4

LOWER AF RECURRENCE rate and SHORTER PROCEDURE

TIMES in contact force compared to conventional catheters

was shown in meta-analysis of 8 independent studies

involving 530 patients1

156

173

145

150

155

160

165

170

175

Procedure Times (min)

Contact Force Conventional

35%

46%

0%

5%

10%

15%

20%

25%

30%

35%

40%

45%

50%

AF Recurrence Rate

P=0.009

P=0.004

Using CF catheters was an INDEPENDENT

PREDICTOR OF PROCEDURAL SUCCESS

evaluating all patients undergoing RF ablation

for paroxysmal or persistent AF (n=721)4

Multivariate

Predictors of AF

Recurrence

HR 95% CI

Persistent AF 2.05 1.48-2.83

LA Volume >40ml/m2 1.42 1.04-1.93

CF Use 0.58 0.42-0.79

BMI 1.04 1.01-1.08

AF Duration (years) 1.07 1.04-1.09

61

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


STJ is the only company to have defined optimal contact force parameters through a robust ,

compelling set of clinical studies

Using optimal contact force parameters with TactiCath catheter decreases rate of repeat ablation5

Using optimal contact force parameters with TactiCath catheter decreases patient cost of care one year

after ablation4

DEFINITION OF OPTIMAL CONTACT FORCE PARAMETERS KEY TO

IMPROVED OUTCOMES, LOWER COST

Optimal Contact Force Rate of Repeat Ablation5 Total Cost per Patient in Year After Ablation6

62

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


TECHNOLOGY ADVANTAGES SUGGEST STJ SHARE

CAPTURE OPPORTUNITY

STJ’s proprietary sensor technology advantages:

Fiber optic sensing allows force to be measured closer to tip where power applied, allow uninhibited use of long

introducer sheath

50Hz sampling rate allows for visualization of transient peaks with cardiac movement and increased real-time

feedback

No calibration required, which may save time and shorten procedures

* Data from the TactiCath catheter are applicable to the TactiCath Quartz catheter as the design modifications made to the Tact iCath catheter were fully verifiable in

bench testing. The concept and working principle of the optical force sensor did not change

TactiCath™ catheter SmartTouch catheter

SmartTouch SF Lateral Contact Force measurements

showed error up to 41.7 g in lateral orientation7

A separate study characterized the contact force accuracy

of the TactiCath™ catheter. Results of this study showed

mean error was ≤ 1 g*8

63

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


STJ ABLATION BUSINESS FUELED BY TACTICATH™ QUARTZ

>7% unit share gain in irrigated advanced ablation

in the U.S. since the launch of TactiCath Quartz9

Momentum continues to build with >350

TactiCath™ Quartz catheter accounts in the U.S.10

TactiCath represents over 50% of STJ’s U.S.

irrigated portfolio11

Expect approval of TactiCath in Japan 2H 2016

64

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


FLEXABILITY™ ABLATION CATHETER RECEIVES PRAISE FOR

HANDLING, TIP PERFORMANCE

STJ irrigated portfolio growth outpaced estimated market growth in Japan by >10

percentage points in 201512

FlexAbility rapidly grew to represent 58% of STJ’s Japan irrigated portfolio within

the first year of launch13

Validated STJ’s next generation handle-shaft combination as the right platform of

the future

Next generation shaft: reliability, accuracy and consistent performance

Advanced handle-shaft combination: Maneuverability with comfort and ease of use

Distinct advantages of unique flexible tip

In recent preclinical work14, the FlexAbility™ ablation catheter showed comparable

lesion sizes to competitive catheters and had:

Significantly lower rate of steam pop when compared to ThermoCool™ SF

Less instances of char when compared to ThermoCool™

65

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

66

STJ ABLATION SHARE CAPTURE IN 2015 JUST THE BEGINNING

Gained over 4 points of U.S. ablation catheter share

Increased STJ ablation catheter penetration with current NavX users globally

Anticipate continued FlexAbility, TactiCath adoption in approved geographies

Expect approval of TactiCath in Japan 2H 2016

FlexAbility ablation catheter TactiCath Quartz ablation

catheter Ampere RF

generator

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


A REVOLUTION IN CARDIAC MAPPING:

AUTOMATED, FLEXIBLE AND PRECISE

67

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


EnSite Precision Module, Sensor EnabledTM*

FlexAbility Ablation Catheter, Sensor

Enabled***

AdvisorTM FL Circular Mapping Catheter, Sensor EnabledTM**

EnSite Precision

Surface Electrode Kit*

EnSite AutoMap* AutoMark* EnSite Precision Software v2.0*

A comprehensive launch of tools and software throughout 2016

ENSITE™ PRECISION CARDIAC MAPPING SYSTEM

*510K pending.


***PMA pending review

Excludes China

68

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


EnSite Precision* CARTO Rhythmia

Automated HD Mapping +

TurboMap feature

Flexible Workflow

Clinically validated Contact

Force parameters

Integrated Lab

Automated Lesion Marking

Proven Platform (Used in

100,000’s of procedures)

Fully Integrates Contact Force

Leverage Impedance AND

Magnetics coordinate systems

HOW DOES PRECISION STACK UP AGAINST THE CURRENT

GENERATION SYSTEMS

*510K pending. 69

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


Designed for improved system and software ease of use

Anticipate improved data acquisition and speed of

acquisition in everyday use, for all procedure types

Faster decision-making with both positive and negative

morphology matching score15, 16

Faster, more accurate map creation with greater

consistency across cases15, 16

Secondary arrhythmias mapped up to 10x faster with

TurboMap feature

Enhanced VT mapping with automated morphology

matching capability15,16 and automatic catheter ectopy

rejection

NEW SOFTWARE PLATFORM* IS A GAME CHANGER

EnSite™ AutoMap Module, TurboMap Feature

*510K pending 70

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE



BULLET GUIDE

BULLET GUIDE


Only system to optimally integrate magnetic and

impedance data

3-D models with CT-scan-like detail – 27x†† higher

point density

Automated lesion marking guidance with the AutoMark

module17

Easily visualize scar tissue – integration

of delayed enhancement MRI imaging17,18

SparkleMap feature enables easy visualization of

voltage pathways on a single map

Customizable dashboard

Tailor patient therapy and streamline workflow

SYSTEM OPTIMIZED FOR TAILORED PATIENT THERAPY*

†† Based on minimum distance allowed between 3-D model points with Precision system versus

previous EnSiteTM VelocityTM system.

AutoMark Module

SparkleMap Feature

*510K pending

71

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


INITIAL FEEDBACK VERY POSITIVE

Initial cases have been performed as part of a limited market release at 3

centers in Germany starting January 26

The EnSite Precision Cardiac Mapping system* was used in a variety of

procedures including atypical flutter, paroxysmal and persistent AF, and VT

System performance has been excellent through challenging procedure

dynamics such as: multiple patient defibrillations, fluid loading, lengthy

procedures times, and complex arrhythmia diagnosis and treatment

Limited market release is expected to continue in Italy and France in

coming weeks, followed by a full market release in 2Q 2016

Anticipate 510k clearance 1H 2016

“Improvements to model precision, model stability, and

mapping automaticity were significant and have delivered

the next generation of mapping technology to Leipzig.” - Prof. Gerhard Hindricks

EHRA President

EP Director, Heart Center, University of Leipzig

“Improvements to model precision and model stability were

significant. EnSite Precision addressed the concerns that

caused me to stop using EnSite Velocity about two years ago.” - Dr Christopher Piorkowski

EP Director, Heart Center, University of Dresden

“This system is exactly what I hoped it would be. AutoMap is

great. Very fast. Feels like the mapping data is more reliable” - Prof. Isabel Deisenhofer

Head Senior Physician, German Heart Center, Munich

Germany

*510K pending 72

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


AMPLATZER AMULET: LEFT ATRIAL APPENDAGE

73

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE

BULLET GUIDE BULLET GUIDE We are a veteran in this space with a significant implant base and over

5 years of experience

STJ is the market leader in Europe

Ease of use

Broad size matrix

Complete seal of left atrial appendage

We plan to initiate global IDE Study in 2H 2016

Encouraging, on-going discussions with the FDA and CMS

Randomized clinical trial vs. approved BSX devices

LAA closure is an attractive, emerging opportunity. IDE study expected to begin in 2016

LEFT ATRIAL APPENDAGE (LAA) OCCLUSION

$-

$30

2011 2012 2013 2014 2015

STJ International LAA Revenue

Dollars in millions

*Constant Currency Compounded Annual Growth Rate

Product not available for sale in the U.S.; remains in development 74

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


NEXT GENERATION CONFIRM: INSERTABLE

CARDIAC MONITOR

75

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


Insertable Cardiac Monitor for Long-Term Arrhythmia Diagnosis

Drive share gains in >$600M market with low double digit growth

Small device size (<1.5cc)

Simple insertion procedure requiring minimal time and resources. Intuitive one-touch programming

Automatic wireless connectivity to Merlin.net

Simplified reports to facilitate monitoring and diagnosis

Expect CE Mark 2H 2016 and FDA clearance 1H 2017

NEXT GENERATION CONFIRM™

Incision and Insertion Tools

Next Generation Confirm Patient App (myMerlin) for iOS & Android

Remote Care (Merlin.net)

Product not available for sale; remains in development. 76

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE

BULLET GUIDE BULLET GUIDE Only company to offer full Integrated Lab – improving service offerings

Comprehensive training and on-site support

Contract/payment options with full purchase, complement of hardware and disposables

Offering our customers the broadest portfolio of solutions

END TO END EP/AF SOLUTION FROM STJ PROVIDES HOSPITALS,

PURCHASING TEAMS AND CONSUMERS AN ADVANTAGE

Lab Features: EnSite Precision™ cardiac mapping system; VantageView™ HD monitoring system;

ViewMate™ ultrasound console; MediGuide™ technology; WorkMate Claris™ recording system

77

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


AF is one of the best growth stories in MedTech

WW market is expected to be over $4 billion and growing low double digits

STJ continues to have the deepest, broadest and most technologically advanced AF portfolio in the

industry

Demonstrated catheter technology leadership in 2015 with FlexAbility and TactiCath and expect to

continue to take additional ablation catheter share in 2016

STJ continues to see LAA occlusion as an attractive market and expects to begin an IDE study in

2016

Enter the insertable cardiac monitor market and the launch of the EnSite Precision Cardiac Mapping

System offer significant growth opportunities in 2016 and beyond

Market leading technology and most comprehensive EP portfolio

SUMMARY

78

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


TRADITIONAL CRM: A PATH TO

RECOVERY IN THE U.S. Eric Fain, M.D., Group President

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE




WW TRADITIONAL CRM MARKET DYNAMICS

Market Dynamics

Low, single-digit unit growth offset by

pricing pressure

U.S. ASP pressure partially offset by shift

to CRT, increased de novo mix, and

premium for new technologies

OUS implants steady and positive

Japan bi-annual reimbursement cuts in

2016

49% 51%

Pacemakers (single & dual chamber)

ICDs (single & dual chamber)

2016* Market Growth

WW: flat

U.S.: -3% to -1%

Intl: 0% to 2%

2016 Market Revenue >$6.6B

Market Growth*: Flat

80 * excludes the impact from currency


CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

81

A PATH TO CRM SHARE RECAPTURE

Multiple new product launches in 2016 and 2017 that return our CRM business to

technology leadership

Expect to have new MRI labeled device submissions and launches across CRM

product segments in key markets globally

Once approved in the U.S., MultiPoint™ CRT Pacing and Nanostim™ leadless

pacemaker expected to provide competitive advantage in U.S. contracting

Continued growth and leadership in heart failure and AF improve the economics,

investment, and competitiveness of our CRM business

We are uniquely positioned to partner with hospitals by contracting across the

cardiovascular service line

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

82

RETURN TO GLOBAL TECHNOLOGY LEADERSHIP IN CRM

The St. Jude Medical CRM portfolio demonstrates our leadership with innovative technology solutions

1 Launched in EU as part of post market clinical trial 2 IDE study completion in 2016 in United States

Smallest, longest

lasting wireless MRI

Pacemaker

New standard in CRT

pacing

Leadership in leadless technology

High Voltage MRI

portfolio Arrhythmia diagnosis

Assurity MRI™ Pacemaker* Nanostim™ Leadless

Pacemaker* MultiPoint™ Pacing*

MRI labeling for existing Ellipse™

& Fortify Assura™ ICDs, and

Quadra Assura™ CRT-D devices*

EU: Launched

U.S.: 1H’16

JPN: Launched

EU: Launched

U.S.: 2H’16

EU: Launched1

U.S.: 2H’16

EU: Launched

U.S.: 1H’172

JPN: Launching (ICD)

2H’16 (CRT-D)

Next Generation

Confirm™

Insertable Cardiac Monitor*

EU: 2H’16

U.S.: 1H’17

*Caution - INVESTIGATIONAL DEVICE, LIMITED BY FEDERAL (OR UNITED STATES) LAW TO INVESTIGATIONAL USE.

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

83



1H 2016 U.S. launch of Assurity MRI™ pacer

World’s smallest, longest lasting wireless,

remotely managed, MRI pacemaker

Efficient workflow using the STJ MRI activator

1H 2016 Japan launch of MRI labelled ICD

Backwards compatible to existing device and

lead technology

Expect to see similar share recapture as LV MRI

launch

2H 2016 Japan launch of MRI labelled CRT-D

2016 MRI LAUNCHES WILL PROVIDE CATALYST FOR GROWTH

1H'12 2H'12 1H'13 2H'13 1H'14 2H'14

Pac

emak

er M

arke

t Sha

re

Impact of MRI Pacemaker Labeling

on STJ Share in Japan

Competitive

MRI PM launch

STJ MRI PM

launch

U.S. IDE clinical trial to support MRI labeling for existing HV devices

Enroll patients previously implanted with STJ HV devices

Endpoint based on 30-day follow-up of ~150 patients

Expect IDE completion in 2H 2016, launch in 1H 2017

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

84



Clinical Summary

Over 1,000 Nanostim™ implants worldwide

Leadless II Study results presented at ESC’15 and in NEJM

Building back momentum in Europe with post-market registry

FDA Panel meeting scheduled for February 18, 2016

Expect U.S. launch 2H 2016

Product Characteristics

Smallest introducer size

Demonstrated chronic retrievability

Expect greater longevity than traditional VVI pacers

MRI labeling

Peri-operative complication rates similar to traditional VVI pacers with

absence of long-term adverse events observed

Dual chamber leadless pacing system development continues

to make progress

NANOSTIMTM LEADLESS PACEMAKER*


CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

85

SUMMARY

In 2016 our product cycle is a path to return STJ to technology leadership in CRM and

provide a foundation for sustained growth

Growth and share recapture in our CRM business will be driven by key product

introductions in 2016 including:

Assurity MRI (U.S.)

HV MRI (Japan and U.S. IDE)

MultiPoint Pacing (U.S.)

Nanostim (U.S.)

Next Generation Confirm™ Insertable Cardiac Monitor (OUS)

As momentum continues to grow in our AF and HF franchises, we expect to see increasing

benefit to our traditional CRM franchise as we partner and align with our customers to

address their greatest unmet needs

CENTER

CENTER

CONTENT MARGIN CONTENT MARGIN

FOOTER FOOTER

HEADER GUIDE

CONTENT GUIDE

SUBHEAD GUIDE


NEUROMODULATION: BUILDING

THE MOST COMPREHENSIVE

PORTFOLIO Keith Boettiger, Sr. V.P. & General Manager,

Chronic Pain & Movement Disorder Therapies

CENTER

CENTER


FOOTER FOOTER

HEADER GUIDE

CONTENT GUIDE

SUBHEAD GUIDE


NEUROMODULATION MARKET OVERVIEW

Key Market Dynamics

Market remains underpenetrated

Oral opioid use under scrutiny

(especially U.S.) creating favorable

market conditions for effective, non-drug

therapies

Replacement cycle driving new units

(expect double digit growth of

replacements in U.S.)

Stable ASPs despite new competition,

driven by premium price capture for new

technologies

Competition from new entrants driving

market growth as awareness is raised

87

2016 Market Revenue >$2.4B

Market Growth*: Mid to high-single digits

67% 8%

2% 23%

Traditional Spinal Cord Stimulation (SCS)

Radio Frequency Ablation (RFA)

Dorsal Root Ganglion (DRG)

Deep Brain Stimulation (DBS)


WW: 7%-9%

U.S.: 6%-8%

Intl: 8%-10%



CENTER

CENTER


FOOTER FOOTER

HEADER GUIDE

CONTENT GUIDE

SUBHEAD GUIDE


TREATING THE CHRONIC PAIN PATIENT

88

CENTER

CENTER


FOOTER FOOTER

HEADER GUIDE

CONTENT GUIDE

SUBHEAD GUIDE


PATIENTS ENDURE LONG, COMPLICATED PATH

Surgeon (General

Orthopedic) Referral

Diag-

nosis

Treat-

ment

Internal Medicine/GP Non-Interventional Pain

Management Interventional Pain

Management

Non-

Opioids

History

Physical Exam

Spine Surgeon Surgeon

Exercise

Psychologi-

cal Therapy

Physical

Therapy NSAIDS

OTC Meds

History History

Non-

Opioids

Injections Surgery

Exercise

Physical

Therapy

TENS NSAIDS

OTC Meds

NSAIDS

TENS Long Acting

Opioids

Opioids

OTC Meds

Physical

Therapy Exercise

Non-

Opioids

Non-

Opioids

SCS

Trial Pump

EMG

(PM&R)

NSAIDS

Physical

Therapy RFA

Injections

Non-

Opioids

Injections SCS

Implant

Exercise

2nd surgery

Physical

Therapy NSAIDS

OTC Meds

Non-

Opioids Exercise

Physical

Therapy NSAIDS

OTC Meds

3 – 5 Steps

6 mo. – 4 yrs. 2 – 8 Steps

6 mos.– 1 yr. 2 – 8 Steps

6 mos.– 2 yrs. 3 – 8 Steps

2 – 5 yrs 3 – 8 Steps

2– 6 yrs. 3 – 8 Steps

6 mos.– 4 yrs.

Path to treat pain is long and fragmented

Patients often desperate to resolve or reduce pain

Patients typically end at long-term opioid therapy at risk of addiction

Clinical and economic data demonstrate benefits of SCS earlier in the care continuum

89

CENTER

CENTER


FOOTER FOOTER

HEADER GUIDE

CONTENT GUIDE

SUBHEAD GUIDE


SPINAL CORD

STIMULATION

Burst gaining momentum where

approved*

SUNBURST RCT preliminary

results demonstrate superiority

vs. tonic

Invisible trial system: discreet,

convenient and Burst-enabled

trial experience**

iPod Touch and iPad Mini

leverage familiar iOS for

consumer friendly peripherals

RADIOFREQUENCY

ABLATION (RFA)

~$200M global market

~90% SCS implanters also use

RFA

Full line of RFA products including

generators, electrodes and

cannulae

Marketed in ~70 countries

DRG becoming standard of care for

Complex Regional Pain Syndrome

(CRPS) and peripheral nerve injury

internationally

ACCURATE trial demonstrates

superiority vs. conventional SCS

Estimated CRPS prevalence is 20%

of global market (DRG therapy

uniquely positioned to treat)

Groundswell of clinician excitement

for new technology to treat a poorly

treated patient group

DRG Launch: FDA approval

expected 1H 2016

DRG*

90

STJ IS UNIQUELY POSITIONED TO SURROUND THE PAIN PATIENT


**In selected geographies where approved

CENTER

CENTER


FOOTER FOOTER

HEADER GUIDE

CONTENT GUIDE

SUBHEAD GUIDE


BURST THERAPY IS A PROPRIETARY ADVANCED

WAVEFORM PROVEN TO DELIVER SUPERIOR RESULTS

91

CENTER

CENTER


FOOTER FOOTER

HEADER GUIDE

CONTENT GUIDE

SUBHEAD GUIDE


In addition to SUNBURST randomized clinical trial, clinical evidence continues to grow:

German observational study shows STJ Burst equal to or better than HF-10 in head-to-head comparison

in 16 FBSS patients (>70% back pain with or without leg pain) randomized and blinded demonstrated 3

key findings1:

1. 100% trial conversion to Burst and 75% trial conversion to HF 10 (2 failures)

2. Both Burst and HF-10 achieved reduction in VAS for back pain that were not significantly different

3. Burst achieved significantly lower VAS for leg pain (p< 0.009)

Expect Burst U.S. approval and launch 2H 2016

WE ARE POISED TO TAKE SHARE WITH PROVEN STJ BURST

92

Limited (~10%) market penetration with advanced

waveforms through 2015

STJ and one competitor with advanced waveforms

represent significant market share opportunity

Recent success in Australia demonstrates our

competitive position:

Australia market share leader*

Q1 2015 Pre-BURST: ~24%

Q4 2015 Post-BURST: ~31%

2014 2015 2016

New Waveforms (SCS)

Adv Waveform Penetration Adv Waveform Opportunity

4%

96% 91%

9%

85%

15%

*Based off of revenue, PWC Consortium data Q1 and Q4 2015

CENTER

CENTER


FOOTER FOOTER

HEADER GUIDE

CONTENT GUIDE

SUBHEAD GUIDE


93

Significantly improved pain outcomes

More than 90% of patients preferred Burst over tonic SCS with better pain relief cited as the primary

reason3-6

Almost 95% of tonic responders experienced a greater reduction in NRS score during Burst

stimulation7

Provided pain relief superior to tonic for overall, trunk, and limb pain6

Demonstrated ability to rescue prior failures

62.5% of non-responders responded to Burst8

Preferred by patients while preserving patient choice

69% of patients preferred Burst (p<0.001) 9

21% of patients still preferred Tonic stimulation and only STJ can provide both options in a single

solution9

Improved workflow

Burst required 50% fewer office visits and lasted 10% as long as regular visits10

GROWING EVIDENCE FOR BURST THERAPY

Caution - INVESTIGATIONAL DEVICE, LIMITED BY FEDERAL (OR UNITED STATES) LAW TO INVESTIGATIONAL USE

CENTER

CENTER


FOOTER FOOTER

HEADER GUIDE

CONTENT GUIDE

SUBHEAD GUIDE


Recharge-Free Platform Invisible Trial MRI

TREATING THE PAIN PATIENT; CREATING PATIENT PREFERENCE

Invisible therapy leading to

patient normalcy

Recharge-free; no patient

burden

First Bluetooth™ enabled

system

First Apple™ iPod touch™

and iPad mini™

programming system

Upgradeable technology

platform

First Bluetooth™-

enabled system

First “on body” trial

system

First Burst & Tonic

Capable EPG

Current state: Head and

extremity MRI

Future state: Full-Body

Conditional MRI

Expect U.S. launch of full-

body MRI in 2H 2016

Improve the patient experience with the Proclaim platform to create preference and

expand patient appetite for SCS trials through improved patient comfort and convenience

94

CENTER

CENTER


FOOTER FOOTER

HEADER GUIDE

CONTENT GUIDE

SUBHEAD GUIDE


STJ DELIVERING MORE FREEDOM

*Estimates based up daily recharging recommended in Nevro Patient Manual 11052 Rev A (2015-01-16)

Traditional Platforms

Step 1 – Identify IPG location suitable for recharging

Step 2 – Place IPG superficially to facilitate charging

Step 3 – Educate patient on charging

Step 4 – Daily or weekly charging for 1-4 hours (frequency dependent)

Proclaim™ Recharge Free Can be implanted almost ~2x deeper than rechargeable options

Designed to reduce patient burden and discomfort

Saves patient 1,825 hours, or 76 full days of recharging, over IPG options with

recommendations of daily charging in 5 years of use*

Gives patients an opportunity to focus on normal daily activities

95

CENTER

CENTER


FOOTER FOOTER

HEADER GUIDE

CONTENT GUIDE

SUBHEAD GUIDE


DORSAL ROOT GANGLION THERAPY IS A UNIQUE

SOLUTION FOR TARGETED PAIN SYNDROMES

96

CENTER

CENTER


FOOTER FOOTER

HEADER GUIDE

CONTENT GUIDE

SUBHEAD GUIDE


Total Knee Replacement

192

122

92

84

37

29 23

15

-10%

0%

10%

20%

30%

40%

50%

60%

-200 0 200 400 600 800 1,000

Ch

ron

ic p

ain

%

Procedures ('000s)

U.S. DRG Market Opportunities ($M)

DRG therapy is designed for focal pain conditions often characterized by nerve injury

Nerve injury is common in the large (and growing) postsurgical pain markets such as hernia, hip and knee

postsurgical pain syndromes

Several physician-initiated studies internationally hold promise to expand indications beyond current labeling

Etiologies are prevalent but poorly treated with current technologies providing a unique opportunity for DRG

therapy

Hernia Surgery

Amputations (lower extremity)

Cardiac Surgery

Mastectomy

Caesarean

Section Total Hip

Replacement Thoracotomy

97

DRG STIMULATION EXPANDS THE MARKET

Notes where DRG is well-positioned

CENTER

CENTER


FOOTER FOOTER

HEADER GUIDE

CONTENT GUIDE

SUBHEAD GUIDE


98

DRG procedure similar to traditional SCS

>400K post-surgical intractable chronic pain patients (U.S. only)11-14

Uses low energy (<10% traditional) with minimal postural effects15

Compared to traditional SCS for patients with chronic lower limb pain

due to CRPS and peripheral causalgia, DRG stimulation provides15:

Sustained and superior pain relief

After 12 months, significantly more DRG stimulation patients achieved pain relief and treatment success

versus control SCS (74.2% vs. 53.0%)

Improved therapeutic targeting

DRG stimulation patients reported better stimulation targeting in their area of pain without extraneous

paresthesia (94.5% vs. 61.2%)

Improved quality of life (QoL) and reduced paresthesia

DRG patients experienced improved QoL measures, psychological disposition and activity levels

After 12 months, more than a third of DRG stimulation patients were experiencing greater than 80% pain

relief with no paresthesia

ACCURATE VALIDATES DRG AS SUPERIOR TO SCS

Caution - INVESTIGATIONAL DEVICE, LIMITED BY FEDERAL (OR UNITED STATES) LAW TO INVESTIGATIONAL USE

CENTER

CENTER


FOOTER FOOTER

HEADER GUIDE

CONTENT GUIDE

SUBHEAD GUIDE


99

Highly motivated and well-trained sales force

Excellent technical and clinical skills

Demonstrated ability to execute during technology reboot

Proven ability to build partnerships with interventional pain physicians and

sell product portfolio

Long-standing respect among physician community

FIELD SELLING ORGANIZATION PREPARED AND EAGER TO EXECUTE

CENTER

CENTER


FOOTER FOOTER

HEADER GUIDE

CONTENT GUIDE

SUBHEAD GUIDE


DBS OPPORTUNITY

100

CENTER

CENTER


FOOTER FOOTER

HEADER GUIDE

CONTENT GUIDE

SUBHEAD GUIDE


101

DEEP BRAIN STIMULATION (DBS) MARKET OPPORTUNITY

6.3M Worldwide

PREVALENCE (no differentiation for race or

culture)

DBS Penetration <1% of the addressable

population have been treated

with DBS <1%

$25B ECONOMIC

IMPACT $25B is the estimated annual

direct and indirect cost of

care for patients with

Parkinson’s disease in the

United States alone

SMALL NUMBER

OF IMPLANTERS ~150 is the number of

surgeons WW who perform

over 50 new cases per year,

~70% academic

150

2016: ~$600M worldwide market with high-single digit to low double-digit growth of

underpenetrated, monopoly market

Stable reimbursement

70% of cases done in less than 100 centers (U.S.)

50% of the market is IPG replacements

CENTER

CENTER


FOOTER FOOTER

HEADER GUIDE

CONTENT GUIDE

SUBHEAD GUIDE


WINNING WITH INNOVATION IN DBS

Patient Peripherals Infinity Platform Directional Lead

User-friendly Apple™

mobile digital devices

First Apple™ iPod

touch™ programming

system

Programming ease-of-

use for physician

App-based Bluetooth®

wireless communication

Competitive headers

First Apple™ iPad

mini™ programming

system

Upgradeable technology

platform

Steer therapy to avoid

stimulating undesirable

areas such as those that

produce side-effects

Reduce current for battery

longevity

Compatible extensible

extension

Platform engineered to fuel patient independence

DBS Global Launch expected 2H 2016 102

CENTER

CENTER


FOOTER FOOTER

HEADER GUIDE

CONTENT GUIDE

SUBHEAD GUIDE


103

STJ neuromodulation business transformed and positioned to be global technology leader

World-class field selling organization prepared and eager to execute

Only company with a portfolio that surrounds the interventional pain physician and treats chronic pain patients

throughout the continuum of care

Radio frequency ablation

Proprietary SCS Burst waveform with upgradeable capability

Dorsal Root Ganglion (DRG) therapy for targeted pain syndromes

Advanced waveforms show superior results to traditional therapy and only account for ~10% of the market

The ACCURATE study showed that DRG was superior in treating targeted pain syndromes versus tonic

Entering a DBS market that has been starved for innovation for the past 15 years

Directional lead technology as the future standard of care

Devices engineered for patient independence: Apple™ consumer devices and simplified programming

SUMMARY

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


CARDIOVASCULAR: PRODUCTS

TO WATCH IN 2016 Phil Ebeling , V.P. and Chief Technology Officer

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE




CARDIOVASCULAR – THE MARKET

Market Dynamics

Strong double digit TAVR market growth

driven by expansion into lower risk patients

Tissue valves remain the gold standard for

most patients with aortic stenosis

WW market expected to continue to grow low-

single digits

Strong double digit growth in percutaneous

heart pumps

U.S. reimbursement established

PCI optimization market expected to grow

low double digits

Upcoming OCT reimbursement for U.S.

physicians

34%

24% 4%

13%

9%

6% 4% 6%

TAVR Surgical Valves PFO/CHD

PCI Optimization Closure Other

PHP Embolization


Market Growth*: High-single to low

double digits




WW: 9%-11%

U.S.: 12%-13%

Intl: 6%-8%

105

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE

BULLET GUIDE BULLET GUIDE Significant market opportunity

Strong double digit market growth driven by expansion into

lower risk patients

Consistent, positive physician feedback

Ease of use: prep, delivery, deploy and recapture, profile

Low rate of permanent pacemakers

IDE enrollment ongoing

Strong group of enthusiastic enrolling centers

Competitive trial recently completed enrollment

Exceeded Q4 2015 expectations

Key contracts awarded in Germany, Switzerland, Italy,

Nordics

First full quarter offering full portfolio of valve sizes

Full launch of a comprehensive PorticoTM transcatheter aortic valve size offering in international

markets, and a fully enrolling U.S. IDE provides meaningful growth in 2016

STJ IS AN EMERGING LEADER IN THE TRANSCATHETER AORTIC

VALVE MARKET

$0

$2

$4

2015 2016 2017 2018 2019 2020R

even

ue

(bill

ion

s)

TAVR WW Market (‘15-’20 CAGR: ~18%)

106 *Caution - INVESTIGATIONAL DEVICE, LIMITED BY FEDERAL (OR UNITED STATES) LAW TO INVESTIGATIONAL USE

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


A self-expanding, repositionable and retrievable transcatheter

aortic valve**

PORTICO IDE TRIAL UPDATE*

Trial Design:

A prospective, multi-center, randomized-controlled study of TAVR in patients at high or

extreme risk for surgical AVR. 1,206 randomized subjects at 60 U.S. centers.

Portico Devices Studied:

23, 25, 27, 29 mm valves with transfemoral and transaortic/subclavian delivery systems

Control: Commercially available TAVR

Primary Endpoints:

Safety composite (mortality, stroke, bleed, AKI, Vasc Comp) at 30 days

Effectiveness composite (mortality, stroke, > moderate AI) at 1 year

Follow-up: 30 days, 6 months, 1, 2, 3, 4 and 5 years

** Repositionable and retrievable until fully deployed


CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE




Scope:

Features to improve placement accuracy, ease of use, profile and trackability

Further improve paravalvular leak (PVL) performance

Expanded valve size offering (18mm – 30mm annulus size)

Transfemoral/subclavian/transaortic approaches

Product Overview:

Improved positioning accuracy with a stability layer

Improved valve placement with coaxial alignment during delivery

Reduced profile in combination with expandable sheath

Improved handle ease of use and ergonomics

Improved PVL performance with the addition of sealing feature

PORTICO NEXT GENERATION*

**Product not available for sale; remains in development 108

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


Trifecta GT valve expected to launch globally in 2016 based off best-in-class hemodynamic

Trifecta platform

TRIFECTA WITH GLIDE TECHNOLOGY *

Tissue Valve Market

Remain the gold standard for most patients with aortic stenosis

WW market expected to continue to grow low-single digits

Trifecta GT

Next generation Trifecta valve

Improved ease of use while maintaining exceptional

hemodynamic performance

Improvement areas include: flexible sewing cuff,

streamlined holder, enhanced radiopacity

Initiate launch in key geographies in 1H'16

Trifecta GT

*Caution – NOT APPROVED IN THE UNITED STATES. NOT AVAILABLE IN ALL GEOGRAPHIES. 109

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


PHP addresses a large, growing market and provides meaningful enhancements to competitive

offerings

HEARTMATE PERCUTANEOUS HEART PUMP (PHP)*


Significant future market opportunity

$300M+ in 2016, strong double-digit CAGR

~15% U.S. PCIs are High Risk

Adequate U.S. reimbursement in place

Disrupts traditional relationship between profile

and flow

Ease of use: prep, delivery, deploy and recapture, profile

Low profile, high flow with stability across the aortic valve

Consistent, positive physician engagement

SHIELD II IDE led by leading physicians

High engagement in study completion

15%

U.S. PCIs (~850k/year)

High Risk

110

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE

BULLET GUIDE BULLET GUIDE Trial Design:

Prospective, randomized, multi-center, open-label non-inferiority trial in the U.S. comparing HeartMate PHP to

Abiomed® Impella® 2.5 percutaneous cardiac support system

Trial Objective

Assess the safety and efficacy of the HeartMate PHP in supporting patients with severe symptomatic coronary

artery disease with diminished but stable cardiovascular function, who are undergoing elective or urgent high

risk percutaneous coronary interventions (PCI) but are not candidates for coronary artery bypass graft (CABG)

surgery

Scope

Up to 60 sites

425 patients randomized 2:1 (PHP: Impella® 2.5)

IDE Trial is evaluating the use of Heartmate PHP to support patients undergoing a high risk PCI

procedure

HEARTMATE PHP™ SHIELD II TRIAL*


CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


STJ continues to drive the PCI Optimization market through advancing the standard of care

with OCT and FFR

PERCUTANEOUS CORONARY INTERVENTION (PCI) OPTIMIZATION

PressureWire X* next generation FFR

pressure guidewire with excellent

steerability, wireless connectivity

and designed to be the most

reliable sensor technology

available

OPTIS Mobile brings the value of

Angiographic co-registration to the

OCT and FFR mobile cart system

Continued market opportunity

OCT/FFR market is projected to grow more than 12% (CN) in

2016 to ~$450 million WW

STJ is the leader in technology development

OPTIS Integrated, OPTIS Mobile with Angio Co-Registration,

PressureWire X*

Legacy of strong clinical data providing strong

clinical and economic outcomes

FFR: FAME I, FAME II, FAME III

OCT: ILUMIEN I, ILUMIEN II, ILUMIEN III


112

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE

BULLET GUIDE BULLET GUIDE At the October 2015 CPT Editorial Panel meeting, the AMA met and decided specific action relating to the use of OCT

As of Jan 1, 2017, the professional coding to describe use of OCT will fall under CPT codes 92978 and 92979, the same

codes as IVUS

The professional component (physician payment) will now be applicable to both OCT and IVUS (vs. IVUS only)

Clinical utility was supported by the publications on the utilization of OCT for PCI optimization, such as ILUMIEN I and

ILUMIEN II studies

Through STJ’s continued investment in clinical data and strong physician advocacy, improved

reimbursement will begin January 1, 2017

OCT REIMBURSEMENT PLANNED FOR U.S. PHYSICIANS

113

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


Market opportunity: >100,000

patients/year with a cryptogenic stroke

and PFO in the U.S.

AMPLATZER™ PFO Occluder is superior

to medical management in reducing

recurrent cryptogenic ischemic stroke

Collaborating with FDA in preparation for

an FDA Panel Meeting 1H’16

Long-term data recently presented at TCT affirm the clinically meaningful benefit of Amplatzer PFO

closure to reduce the likelihood of recurrent cryptogenic stroke

AMPLATZER PATENT FORAMEN OVALE (PFO) CLOSURE*


1

114

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


STJ remains committed to renal denervation therapy for hypertension and expects to

commence global IDE in 2016

HYPERTENSION – ENLIGHTN RENAL DENERVATION*

*Not available for sale in the U.S.

Significant future market opportunity

1.2B Worldwide prevalence

STJ preclinical efforts validate concept

Sustained blood pressure reductions in hypertensive swine

model

Provides confidence in treatment effect

STJ expects to begin global IDE in 2016

Sham-controlled, randomized controlled trial

On-going discussions with FDA

Global thought leader steering committee

115

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

116



Portico*: Competitive TAVR device provides a meaningful growth engine in 2016

First full quarter of all sizes in Europe exceeded expectations

Expect to continue to accelerate U.S. IDE enrollment

Trifecta GT**: Expected to launch globally in 2016 based off best-in-class

hemodynamic Trifecta platform

Heartmate PHP*: Provides meaningful enhancements to competitive offerings for

high-risk PCI patients

PCI Optimization: Through continued investment in clinical data and strong physician

advocacy, improved reimbursement will begin January 1, 2017

OPTIS Integrated, OPTIS Mobile with Angio Co-Registration, PressureWire X**

Amplatzer PFO Closure*: FDA panel meeting (1H’16)

EnligHTN Renal Denervation**: Committed to renal denervation therapy for

hypertension and expect to commence global IDE in 2016

SUMMARY


**Caution - NOT APPROVED IN THE UNITED STATES. NOT AVAILABLE IN ALL GEOGRAPHIES.

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

117



Q&A Panel Moderator:

Mike Rousseau, President and CEO

Panelists:

Keith Boettiger, S.V.P. & General Manager, Chronic Pain and Movement Disorder Therapies

Allen Burton, M.D., Medical Director, Neuromodulation, Movement Disorders & Pain, and

V.P, Medical Affairs

Phil Ebeling, V.P., Chief Technology Officer


CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

118

THANK YOU

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

119

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


1. Go A, et al. Heart Disease and Stroke Statistics 2013 Update: A Report from the American Heart Association. Circulation. Published online

December 12, 2012.

2. Blecker, S, Paul, M et al. Heart failure-associated hospitalizations in the United States. JACC 2013 61:12 (1259-1267).

3. Lopez-Sendon, J. Heart failure today: A paradigm shift. Medicographia. 2011;33(4):363-9.

4. Costs to treat heart failure expected to more than double by 2030. http://newsroom.heart.org/news/costs-to-treat-heart-failure-expected-to-

more-than-double-by-2030. Accessed April 23, 2014.

5. Hunt SA, Abraham WT, Chin MH, et al. 2009 focus update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and

management of heart failure in adults. Circulation. 2009;119(14):e391-479(e437).

6. Corbisiero R, Beau S, Allison S, et al. Intra-operative efficiency of the Quartet left ventricular lead. Presented during Cardiostim 2014, Nice

France. Session 56-65.

7. Boriani et al., Cardiac resynchronization therapy with a novel quadripolar lead decreases complications at six months: preliminary results of

the MORE-CRT trial, ESC 2014, FP# 887.

8. Graham CM, et al. Comparison of Healthcare Utilization and Hospital Costs for Quadripolar versus Bipolar LV Lead Technologies. HRS

2014. San Francisco, California. May 7-10, 2014.

9. Turakhia M et al. Reduced mortality with quadripolar versus bipolar left ventricular leads in cardiac resynchronization therapy. HRS 2014.

PO01-51. Retrospective data analysis.

10. Thibault, B., Dubuc, M., Khairy, P., Guerra, P.G., Macle, L., Rivard, L., ... Farazi, T.G. (2013). Acute haemodynamic comparison of multisite

and biventricular pacing with a quadripolar left ventricular lead. Europace, 15(7), 984–91.

11. Pappone, C., Calovic Z., Vicedomini, G., Cuko, A., McSpadden, L. C., Ryu, K., . . . Santinelli, V. (2014). Multipoint left ventricular pacing

improves acute hemodynamic response assessed with pressure-volume loops in cardiac resynchronization therapy patients. Heart

Rhythm, 11(3), 394-401.

12. Endrj, M., Ballari, G. P., Goletto, C., Rossetti, G., & Vado, A. (2015). Characterization of ventricular activation pattern and acute

hemodynamics during multipoint left ventricular pacing. Heart Rhythm, 12(8):1762-9.

HF REFERENCES

120

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


13. Osca, J., Alonso, P., Cano, O., Andres, A., Melero, J., Sancho-Tello, M. J., & Olague, J. (2015). Multipoint pacing in left ventricle with a

quadripolar lead improves cardiac dyssynchrony and haemodynamics in comparison to conventional pacing. Heart Rhythm, 12(5). pO02-

188

14. Forleo, G.B., Santini, L., Potenza, D., Di Stolfo, G., Locatelli, A., Baracca, E., ... Zanon, F. (2015). Impact of multi-point left ventricular

pacing on QRS duration and left ventricular ejection fraction: preliminary results from a multicenter prospective study. Heart Rhythm, 12(5).

PO04-183.

15. Park, S.J., Chun, K., Park, K., On, Y.K., Kim, J.S. (2015). More favorable electrical and mechanical reverse remodeling after cardiac

resynchronization therapy with quadripolar versus conventional bipolar lead. Heart Rhythm, 12(5). AB28-05.

16. Pappone, C., Calovic Z., Vicedomini G., Cuko, A., McSpadden, L. C., Ryu, K., . . . Santinelli, V. (2015). Improving cardiac

resynchronization therapy response with multipoint left ventricular pacing: Twelve-month follow-up study. Heart Rhythm. 12(6):1250-8.

17. Pappone, C., Calovic Z., Cuko, A., McSpadden, L. C., Ryu, K., . . . Santinelli, V. (2015). Multipoint left ventricular pacing provides additional

echocardiographic benefit to responders and non-responders to conventional cardiac resynchronization therapy. European Heart Journal

Supplements, 17(Suppl A), A12-A17."

18. Cleland, J.G,, Louis, A.A., Rigby, A.S., Janssens, U., Balk, A.H,, TENS-HMS Investigators. (2005) Noninvasive Home Telemonitoring for

Patients With Heart Failure at High Risk of Recurrent Admission and Death: The Trans-European Network-Home-Care Management

System (TEN-HMS) study. JACC, 45, 1654-1664.

19. Chaudhry, S. I., Mattera, J. A., Curtis, J. P., Spertus, J. A., Herrin, J., Lin, Z., . . . Krumholz, H. M. (2010). Telemonitoring in patients with

heart failure. The New England Journal of Medicine, 363, 2301-2309.

20. Koehler, F., Winkler, S., Schieber, M., Sechtem, U., Stangl, K., Böhm, M., . . . Telemedical Interventional Monitoring in Heart Failure

Investigators. (2011). Impact of remote telemedical management on mortality and hospitalizations in ambulatory patients with chronic heart

failure: The Telemedical Interventional Monitoring in Heart Failure study. Circulation, 123, 1873-1880.

21. Angermann, C.E.,Stork,S., Gelbrich, G., Faller, H., Jahns, R., Frantz, S., …Ertl,G. (2012). Mode of Action and Effects of Standardized

Collborative Disease Management on Mortality and Morbidity in Patients with Systolic Heart Failure: The Interdisciplinary Network for Heart

Failure (INH) Study. Circ Heart Failure 2012;5;25-35.

HF REFERENCES

121

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


22. Ong, M.K., Romano, P.S., Edgington, S., Aronow, H. U., Aierbach, A.D., Black, J.T., . . . BEAT-HF Research Group. The Better

Effectiveness After Transition – Heart Failure Study - Remote Patient Management After Discharge of Hospitalized Heart Failure Patients.

AHA 2015 LBCT.

23. Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, Strickland W, Neelagaru S, Raval N, Krueger S, Weiner

S, Shavelle D, Jeffries B, Yadav JS; CHAMPION Trial Study Group. Wireless pulmonary artery haemodynamic monitoring in chronic heart

failure: a randomised controlled trial. Lancet. 2011 Feb 19;377(9766):658-66.

24. Adamson PB, Abraham WT, Bourge RC, Costanzo MR, Hasan A, Yadav C, Henderson J, Cowart P, Stevenson LW. Wireless Pulmonary

Artery Pressure Monitoring Guides Management to Reduce Decompensation in Heart Failure with Preserved Ejection Fraction. Circ Heart

Fail. 2014.

25. Adamson PB, Abraham WT, Bauman j, Yadav J. Impact of Wireless Pulmonary Artery Pressure Monitoring on Heart Failure

Hospitalizations and All-Cause 30-Day Readmission in Medicare-Eligible Patients with NYHA Class III Heart Failure: Results from the

CHAMPION Trial. AHA. Nov 2014 Circulation , 130, A16744.

26. Abraham, W. T., Adamson, P. B., Stevenson, L., Costanzo, M. R., Bourge, R., Bauman, J., & Yadav, J. (2015, March). Pulmonary artery

pressure management in heart failure patients with reduced ejection fraction significantly reduces heart failure hospitalizations and

mortality above and beyond background guideline-directed medical therapy. Abstract 902-04 presented at ACC 2015, San Diego,

California.

27. Abraham, W. T., Adamson, P. B., Stevenson, L. W., Costanzo, M. R., Bourge, R. C., Bauman, J., & Yadav. J. (2015, May). Pulmonary

artery pressure management in heart failure patients with cardiac resynchronization therapy or implantable cardioverter defibrillator devices

significantly reduces heart failure hospitalizations and mortality above and beyond background guide-directed medical therapy. Abstract

AB37-03 presented at HRS 2015, Boston.

28. Abraham, W.T, Stevenson, L.W., Bourge, R.C., Lindenfeld, J…CHAMPION Trial Study Group. Sustained Efficacy of Pulmonary Artery

Pressure to Guide Adjustment of Chronic Heart Failure Therapy: Complete Follow-Up Results from the CHAMPION Randomised Trial.

Lancet. Published Online 2015 Nov 8 [Epub ahead of print].

29. CMS-1632-F and CMS-1632-CN FY-16 Impact File (Final Rule and Correction Notice). Available at:

https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/FY2016-IPPS-Final-Rule-Home-Page.html.

HF REFERENCES

122

https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/FY2016-IPPS-Final-Rule-Home-Page.html




















CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


30. John, Naka, Smedira, et al. Ann Thorac Surg 2011; 92:1406-13.

31. Data on file.

32. Park, Milano, Tatooles, et al. Circulation Heart Failure. 2012; 5:241-248.

33. Miller, Pagani, Russell, et al. NEJM 357:885-896, 2007. Pagani, Miller, Russell, et al. JACC 54:312-321, 2009. Starling, Naka, Boyle, et

al. JACC 57:1890-8, 2011.

34. Slaughter, Rogers, Milano, et al. NEJM 2009; 361:2241-51. Park, Milano, Tatooles, et al. Circ HF 2012; 5:241-248. Jorde, Kushwaha,

Tatooles, et al. JACC 2014; 63:1751-7.

HF REFERENCES

123

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


1. Shurrab, M., et al. (2015, May). Impact of contact force technology on atrial fibrillation ablation: a meta-analysis. JAMA 2015; 4e002476

2. Optimal CF cohort defined as those patients where ≥ 90% lesions ≥10 g

3. Non-optimal CF cohort defined as those patients where < 90% lesions ≥10 g

4. Providencia, R., Khoueiry, Z., Bouzeman, A., et al. (2015, May). Contact-force sensing using the SmartTouch and TactiCath catheter: head-

to-headcomparison and benefit on catheter ablation of paroxysmal and persistent atrial fibrillation. Presented at HRS 2015, Boston.

5. Reddy VY, Dukkipati SR, Neuzil P, Natale A, Albenque JP, Kautzner J, Shah D, Michaud G, Wharton M, Harari D, Mahapatra S, Lambert

H, Mansour M. A randomized controlled trial of the safety and effectiveness of a contact force sensing irrigated catheter for ablation of

paroxysmal atrial fibrillation: results of the TOCCASTAR study. Circulation. 10 Aug 2015. DOI: 10.1161/CIRCULATIONAHA.114.014092.

6. Data presented by Moussa Mansour, MD at AF Symposium 2016, Orlando, FL USA

7. Bourier, F., Hessling, G., Ammar-Busch, S., Kottmaier, M., Buiatti, A., Grebmer, C., . . . Reents, T. (2015). Electromagnetic contact-force

sensing electrophysiological catheters: How accurate is the technology? J Cardiovasc Electrophysiol Journal of Cardiovascular

Electrophysiology.

8. Yokoyama, K., Nakagawa, H., Shah, D., Lambert, H., Leo, G., Aeby, N., . . . Jackman, W. (2008). Novel Contact Force Sensor

Incorporated in Irrigated Radiofrequency Ablation Catheter Predicts Lesion Size and Incidence of Steam Pop and Thrombus. Circulation:

Arrhythmia and Electrophysiology, 1(5), 354-362..

9. Q3 2014 to Q4 2015 unit share gain

10. Total of 413 TactiSys units in Q4 2015 in United States

11. Q4 2015 portfolio mix in the United States

12. STJ unit growth of 31% year over year vs. estimated market growth of 19%

13. FY 2015

14. Winterfield, J., Jensen, J., Gilbert, T., Marchlinski, F., Natale, A., Packer, D., . . . Wilber, D. (2015). Lesion Size and Safety Comparison

between the Novel Flex Tip on the FlexAbility Ablation Catheter and the Solid Tips on the ThermoCool and ThermoCool SF Ablation

Catheters. J Cardiovasc Electrophysiol

AF REFERENCES

124

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


15. Ptaszek, L., Moon, B., Sacher, F., Jais, P., Mahapatra, S., & Mansour, M. (2015). A novel tool for mapping multiple rhythms from a single

mapping procedure. Poster abstract P849. Europace,17(Suppl 3), iii115.

16. Ptaszek, L., Moon, B., Mahapatra, S., & Mansour, M. (2015, Nov). Rapid high density automated electroanatomical mapping using

multiple catheter types. Poster presentation P097. APHRS Scientific Sessions, November 21, 2015, Melbourne

17. St. Jude Medical. Data on File. Report 90214738.

18. St. Jude Medical. Data on File. Report 90202460.

AF REFERENCES

125

CENTER

CENTER


FOOTER FOOTER

HEADER GUIDE

CONTENT GUIDE

SUBHEAD GUIDE


126

1. Kinfe T.M., et. al. 2016. Neuromodulation 2016; E-pub ahead of print. DOI: 10.1111/ner.12379

2. Stirman, T., Hargett, J., Fontenot, H., and Peichel, D. (2015). Evaluating the Invisible Spinal Cord Stimulation Trial System – Results

from the INSTINCTS Study. NANS 2015.

3. De Ridder D, et. al. Neurosurgery 66:986-990, 2010.

4. De Ridder D, et. al. World Neurosurg. 2013;80(5):642-9.e1.

5. Wahlstedt A, et. al. Neuromodulation. 2013;16(5):e227.

6. Courtney P., et. al. Neuromodulation 2015; 18: 361–366.

7. De Ridder, et al. Clinical Journal of Pain, 201412

8. Vanneste, et al. Neuromodulation, 2013

9. Deer, T. Staats, P. Plenary session. NANS 2015

10. SJM. Notes on file. 2015

11. Jorgensen, et al Br J Surg. 2012

12. Kehlet, et al. Lancet. 2006

13. Macrae, W.A. British Journal of Anesthesia .2008

14. Sadosky, et al Pain Practice.2008.

15. Levy R and Deer T. Plenary INS 2015

NEUROMODULATION REFERENCES

CENTER

CENTER

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

CONTENT MARGIN

FOOTER FOOTER

SUB HEAD/

BULLET GUIDE

SUBHEAD/

BULLET GUIDE


1. Carroll, John D. “RESPECT Extended Follow-up Results.” TCT 2015. Moscone Center, San Francisco, CA. October 15, 2015

CARDIOVASCULAR REFERENCES

127

stj 2016 analyst and investor day presentation v2

Investor Relations